[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":195,"collaborators":20,"id":197,"slug":198,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":20,"eligibilityCriteria":203,"healthyVolunteers":199,"sex":204,"minAge":205,"maxAge":20,"enrollmentInfo":206,"targetDuration":20,"studyType":209,"phases":210,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving GSK5471713","EXPERIMENTAL","Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design.",[13],"Drug: GSK5471713",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","GSK5471713","GSK5471713 will be administered at different dose levels based on the dose escalation study design",[9],null,[22],{"name":23,"affiliation":5,"role":24},"GSK Clinical Trials","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[35,57,71,85,99,115,131,145,160,170,185],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"GSK Investigational Site","RECRUITING","La Jolla","California","92093","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.2742,32.84727,{"lat":47,"lon":46},[50,51,54],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":55,"role":56,"phone":20,"phoneExt":20,"email":20},"Rana McKay","PRINCIPAL_INVESTIGATOR",{"facility":36,"status":37,"city":58,"state":59,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Grand Rapids","Michigan","49546",{"type":44,"coordinates":62},[63,64],-85.66809,42.96336,{"lat":64,"lon":63},[67,68,69],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":70,"role":56,"phone":20,"phoneExt":20,"email":20},"Emerson Lim",{"facility":36,"status":37,"city":72,"state":73,"zip":74,"country":41,"countryCode":42,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Philadelphia","Pennsylvania","19107",{"type":44,"coordinates":76},[77,78],-75.16362,39.95238,{"lat":78,"lon":77},[81,82,83],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":84,"role":56,"phone":20,"phoneExt":20,"email":20},"Kevin Zarrabi",{"facility":36,"status":37,"city":86,"state":87,"zip":88,"country":41,"countryCode":42,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"West Valley City","Utah","84119",{"type":44,"coordinates":90},[91,92],-112.00105,40.69161,{"lat":92,"lon":91},[95,96,97],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":98,"role":56,"phone":20,"phoneExt":20,"email":20},"Jose Pacheco",{"facility":36,"status":37,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Melbourne","Victoria","3000","Australia","AU",{"type":44,"coordinates":106},[107,108],144.96332,-37.814,{"lat":108,"lon":107},[111,112,113],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":114,"role":56,"phone":20,"phoneExt":20,"email":20},"Arun Azad",{"facility":36,"status":37,"city":116,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Toronto","Ontario","M5G 2M9","Canada","CA",{"type":44,"coordinates":122},[123,124],-79.39864,43.70643,{"lat":124,"lon":123},[127,128,129],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":130,"role":56,"phone":20,"phoneExt":20,"email":20},"Srikala Sridhar",{"facility":36,"status":37,"city":132,"state":133,"zip":134,"country":119,"countryCode":120,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Montreal","Quebec","H4A 3J1",{"type":44,"coordinates":136},[137,138],-73.58781,45.50884,{"lat":138,"lon":137},[141,142,143],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":144,"role":56,"phone":20,"phoneExt":20,"email":20},"Ramy Saleh",{"facility":36,"status":37,"city":146,"state":20,"zip":147,"country":148,"countryCode":149,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Tokyo","104-0045","Japan","JP",{"type":44,"coordinates":151},[152,153],139.69171,35.6895,{"lat":153,"lon":152},[156,157,158],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":159,"role":56,"phone":20,"phoneExt":20,"email":20},"Kazuki Sudo",{"facility":36,"status":37,"city":146,"state":20,"zip":161,"country":148,"countryCode":149,"cosmosGeoPoint":162,"geoPoint":164,"contacts":165},"135-8550",{"type":44,"coordinates":163},[152,153],{"lat":153,"lon":152},[166,167,168],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":169,"role":56,"phone":20,"phoneExt":20,"email":20},"Yuji Miura",{"facility":36,"status":37,"city":171,"state":172,"zip":173,"country":174,"countryCode":20,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Seoul","Seoul Teugbyeolsi","06351","South Korea",{"type":44,"coordinates":176},[177,178],126.9784,37.566,{"lat":178,"lon":177},[181,182,183],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":184,"role":56,"phone":20,"phoneExt":20,"email":20},"Se Hoon Park",{"facility":36,"status":37,"city":171,"state":20,"zip":186,"country":174,"countryCode":20,"cosmosGeoPoint":187,"geoPoint":189,"contacts":190},"120-752",{"type":44,"coordinates":188},[177,178],{"lat":178,"lon":177},[191,192,193],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},{"name":194,"role":56,"phone":20,"phoneExt":20,"email":20},"Sang Joon Shin",{"type":196,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100618502","phase-1-first-time-in-human-study-of-gsk5471713-in-adults-with-mcrpc-100618502",false,"NCT07332455","First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","A Phase 1\u002F2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","Inclusion Criteria:\n\n* Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.\n* Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n* Progression on ADT and \\>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane based chemotherapy regimens.\n\nExclusion Criteria:\n\n* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.\n* Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion\u002Fexclusion criteria apply.","MALE","18 Years",{"count":207,"type":208},54,"ESTIMATED","INTERVENTIONAL",[211,212],"PHASE1","PHASE2","This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit\u002Frisk of GSK5471713 given as a monotherapy in mCRPC.",[215],"Neoplasms, Prostate",[217,218,17,219],"Metastatic castration-resistant prostate cancer","First-Time-in-Human","Prostate cancer","2026-07-23",{"date":222,"type":223},"2026-07-24","ACTUAL",{"date":225,"type":223},"2026-02-10",{"date":227,"type":208},"2030-03-26",{"name":5,"class":6},11]